ATE419375T1 - Amplifizierung von cyp24 und anwendung dafür - Google Patents

Amplifizierung von cyp24 und anwendung dafür

Info

Publication number
ATE419375T1
ATE419375T1 AT00916145T AT00916145T ATE419375T1 AT E419375 T1 ATE419375 T1 AT E419375T1 AT 00916145 T AT00916145 T AT 00916145T AT 00916145 T AT00916145 T AT 00916145T AT E419375 T1 ATE419375 T1 AT E419375T1
Authority
AT
Austria
Prior art keywords
cyp24
level
cancer
animal
biological sample
Prior art date
Application number
AT00916145T
Other languages
English (en)
Inventor
Donna Albertson
Daniel Pinkel
Colin Collins
Joe Gray
Bauke Ystra
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE419375T1 publication Critical patent/ATE419375T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00916145T 1999-04-02 2000-03-06 Amplifizierung von cyp24 und anwendung dafür ATE419375T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/285,292 US7648826B1 (en) 1999-04-02 1999-04-02 Detecting CYP24 expression level as a marker for predisposition to cancer

Publications (1)

Publication Number Publication Date
ATE419375T1 true ATE419375T1 (de) 2009-01-15

Family

ID=23093617

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916145T ATE419375T1 (de) 1999-04-02 2000-03-06 Amplifizierung von cyp24 und anwendung dafür

Country Status (7)

Country Link
US (4) US7648826B1 (de)
EP (1) EP1255850B1 (de)
JP (1) JP4790127B2 (de)
AT (1) ATE419375T1 (de)
CA (1) CA2367291C (de)
DE (1) DE60041278D1 (de)
WO (1) WO2000060109A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7648826B1 (en) 1999-04-02 2010-01-19 The Regents Of The University Of California Detecting CYP24 expression level as a marker for predisposition to cancer
PT1410011E (pt) 2001-06-18 2011-07-25 Rosetta Inpharmatics Llc Diagnóstico e prognóstico de pacientes com cancro da mama
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
DK2037936T3 (da) 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
KR101691876B1 (ko) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
US9670552B2 (en) 2007-11-30 2017-06-06 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
EP2217728A4 (de) 2007-11-30 2011-01-05 Genomictree Inc Diagonsekit und chip für blasenkrebs mit blasenkrebsspezifischem methylierungsmarkergen
US9670551B2 (en) 2007-11-30 2017-06-06 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9797017B2 (en) 2007-11-30 2017-10-24 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US10113203B2 (en) 2007-11-30 2018-10-30 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US9783857B2 (en) 2007-11-30 2017-10-10 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
US8614071B2 (en) * 2009-12-11 2013-12-24 Roche Molecular Systems, Inc. Preferential amplification of mRNA over DNA using chemically modified primers
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
US9135694B2 (en) 2012-12-04 2015-09-15 General Electric Company Systems and methods for using an immunostaining mask to selectively refine ISH analysis results
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법
CN113267529B (zh) * 2021-05-12 2022-10-25 江西师范大学 一种温度型生物传感器及利用温度型生物传感器检测目标适体的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0960197B1 (de) 1996-07-15 2009-03-25 The Regents Of The University Of California GENE DES 20q13 AMPLIKONS UND DEREN VERWENDUNGEN
US7648826B1 (en) 1999-04-02 2010-01-19 The Regents Of The University Of California Detecting CYP24 expression level as a marker for predisposition to cancer
CA2494572A1 (en) * 2003-12-19 2005-06-19 Cytochroma Inc. Cytochrome p450 24 (cyp24) monoclonal antibody and methods and uses thereof

Also Published As

Publication number Publication date
JP2002540798A (ja) 2002-12-03
WO2000060109A1 (en) 2000-10-12
US20120322674A1 (en) 2012-12-20
EP1255850A4 (de) 2005-02-09
US8173602B2 (en) 2012-05-08
EP1255850B1 (de) 2008-12-31
US20140187441A1 (en) 2014-07-03
JP4790127B2 (ja) 2011-10-12
EP1255850A1 (de) 2002-11-13
US8685929B2 (en) 2014-04-01
DE60041278D1 (de) 2009-02-12
US7648826B1 (en) 2010-01-19
US20100285023A1 (en) 2010-11-11
CA2367291C (en) 2012-05-15
CA2367291A1 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
DE60041278D1 (de) Amplifizierung von cyp24 und anwendung dafür
Liu et al. Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
Hagemann et al. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-α dependent up-regulation of matrix metalloproteases
Moretti et al. β-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
Zhang et al. A lymph node metastatic mouse model reveals alterations of metastasis‐related gene expression in metastatic human oral carcinoma sublines selected from a poorly metastatic parental cell line
DE60238132D1 (de) Patientenklassifizierung
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
Aguado et al. Biomaterial scaffolds as pre‐metastatic niche mimics systemically alter the primary tumor and tumor microenvironment
ATE529535T1 (de) Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
ATE406575T1 (de) Verfahren zur erkennung von medikamentenempfindlichkeit in patienten mit entzündungskrankheiten
AU2004205878A8 (en) Gene expression markers for breast cancer prognosis
WO2004000094A8 (en) Predictive markers in cancer therapy
ATE485366T1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
Pannier et al. High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
WO2002090925A3 (en) Polypeptides and nucleic acids associated with cancer
WO2002077197A3 (en) Methods for diagnosing and monitoring malignancies by screening gene copy numbers
ATE466938T1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
Al Moustafa et al. Up-regulation of E-cadherin by an anti-epidermal growth factor receptor monoclonal antibody in lung cancer cell lines
Ota et al. Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells
AU2002367317A1 (en) Psoriasin expression by breast epithelial cells
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
ATE256120T1 (de) Reagentien für cyp2d fluoreszenztest
DE69636041D1 (de) Nachweis von brusttumorvirus-artigen sequenzen in brustkrebs bei menschen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties